Characterization of a dual <scp>BET</scp>/<scp>HDAC</scp> inhibitor for treatment of pancreatic ductal adenocarcinoma
Xin Zhang(Wuhan University), Jens T. Siveke(German Cancer Research Center)
Cited by 52
Related Papers
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
|Nature Medicine|2015|414
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
|Cancer Discovery|2021|282
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes
|Cell Metabolism|2020|167
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
|Clinical Cancer Research|2022|145